Denali Therapeutics Inc. DNLI Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $390.73M+551% | $208.43M+18.1% | $94.07M+2.0% | $144.31M+89.3% | $60.05M-3.4% | ||
| $600.06M-21.1% | $662.55M+0.8% | $757.24M+1.5% | $757.75M-7.7% | $760.98M-13.2% | ||
| $1.02B+16.4% | $900.66M+4.2% | $882.6M+1.6% | $934.71M+0.7% | $878.64M-9.8% | ||
| $51.73M-10.5% | $52.4M-5.1% | $53.73M+5.7% | $58.72M+22.1% | $57.77M+23.3% | ||
| $36M— | $0— | —— | —— | —— | ||
| $1.27B-0.4% | $1.14B-16.7% | $1.06B-27.4% | $1.17B-22.4% | $1.27B-19.6% | ||
| $40.38M+377% | $505K-95.5% | $6.75M-29.7% | $10.84M-22.2% | $8.46M-28.7% | ||
| $90K— | $83K— | —— | —— | —— | ||
| $110.16M+19.9% | $98.35M-3.8% | $90.15M+3.5% | $91.06M+22.2% | $91.88M+11.3% | ||
| $339.93M+129% | $131.09M-9.3% | $129.42M-4.5% | $139.19M+20.5% | $148.66M+18.3% | ||
| $1.91M+7.6% | $1.89M+6.8% | $1.79M+1.6% | $1.78M+1.5% | $1.78M+1.5% | ||
| -$2.18B-30.4% | -$2.05B-33.3% | -$1.92B-35.0% | -$1.8B-36.4% | -$1.67B-37.3% | ||
| $926.1M-17.5% | $1.01B-17.6% | $926.2M-29.8% | $1.03B-26.0% | $1.12B-22.9% | ||
| $1.27B-0.4% | $1.14B-16.7% | $1.06B-27.4% | $1.17B-22.4% | $1.27B-19.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Denali Therapeutics Inc. cover its short-term obligations?
- Its current ratio is 9.28 — current assets exceed current liabilities.
- Where does Denali Therapeutics Inc.'s balance sheet data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.